262 related articles for article (PubMed ID: 26233684)
1. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.
Lima-Martínez MM; Paoli M; Rodney M; Balladares N; Contreras M; D'Marco L; Iacobellis G
Endocrine; 2016 Mar; 51(3):448-55. PubMed ID: 26233684
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide causes large and rapid epicardial fat reduction.
Iacobellis G; Mohseni M; Bianco SD; Banga PK
Obesity (Silver Spring); 2017 Feb; 25(2):311-316. PubMed ID: 28124506
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Jalaludin MY; Deeb A; Zeitler P; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD; Shankar RR
Pediatr Diabetes; 2022 Mar; 23(2):183-193. PubMed ID: 34779103
[TBL] [Abstract][Full Text] [Related]
4. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
6. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
[TBL] [Abstract][Full Text] [Related]
7. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
9. The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes.
Beljić-Živković T; Marjanović-Petković M; Vuksanović M; Soldatović I; Kanlić D; Topalov D
Srp Arh Celok Lek; 2016; 144(9-10):497-502. PubMed ID: 29652465
[TBL] [Abstract][Full Text] [Related]
10. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Rigby SP; Handelsman Y; Lai YL; Abby SL; Tao B; Jones MR
Endocr Pract; 2010; 16(1):53-63. PubMed ID: 19789153
[TBL] [Abstract][Full Text] [Related]
11. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
13. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
Koren S; Shemesh-Bar L; Tirosh A; Peleg RK; Berman S; Hamad RA; Vinker S; Golik A; Efrati S
Diabetes Technol Ther; 2012 Jul; 14(7):561-7. PubMed ID: 22512265
[TBL] [Abstract][Full Text] [Related]
14. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
15. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients.
Ziyrek M; Kahraman S; Ozdemir E; Dogan A
Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):419-423. PubMed ID: 31324408
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
[TBL] [Abstract][Full Text] [Related]
18. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
Iacobellis G; Gra-Menendez S
Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
